BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30026433)

  • 1. [Two Case Reports of Chemotherapy-Induced Radiation Myositis].
    Nishibuchi I; Wadasaki K
    Gan To Kagaku Ryoho; 2018 Jun; 45(6):1005-1007. PubMed ID: 30026433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
    Yamauchi J; Kanai M; Matsumoto S; Nishimura T; Yazumi S; Kami K; Kawaguchi Y; Yasuda H; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Fukushima M; Doi R; Chiba T
    Pancreas; 2008 Apr; 36(3):327-8. PubMed ID: 18362852
    [No Abstract]   [Full Text] [Related]  

  • 3. Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
    Maemura K; Mataki Y; Kurahara H; Kawasaki Y; Iino S; Sakoda M; Uchikado Y; Arigami T; Uenosono Y; Mori S; Ueno S; Shinchi H; Natsugoe S
    Anticancer Res; 2017 Jan; 37(1):233-237. PubMed ID: 28011497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis.
    Zaima C; Kanai M; Ishikawa S; Kawaguchi Y; Masui T; Mori Y; Nishimura T; Matsumoto S; Yanagihara K; Chiba T; Mimori T
    Jpn J Clin Oncol; 2011 Jun; 41(6):803-6. PubMed ID: 21478179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
    Goji T; Kimura T; Miyamoto H; Takehara M; Kagemoto K; Okada Y; Okazaki J; Takaoka Y; Miyamoto Y; Mitsui Y; Matsumoto S; Sueuchi T; Tanaka K; Fujino Y; Takaoka T; Kitamura S; Okamoto K; Kimura M; Sogabe M; Muguruma N; Okahisa T; Sato Y; Sagawa T; Fujikawa K; Sato Y; Ikushima H; Takayama T
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):615-20. PubMed ID: 26220846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
    Nakachi K; Furuse J; Kinoshita T; Kawashima M; Ishii H; Ikeda M; Mitsunaga S; Shimizu S
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):527-34. PubMed ID: 19967537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.
    Eguchi H; Nagano H; Kobayashi S; Kawamoto K; Wada H; Hama N; Tomimaru Y; Akita H; Sakai D; Satoh T; Kudo T; Isohashi F; Mori M; Doki Y
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):309-15. PubMed ID: 24258457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pancreatic cancer showing complete pathological response to preoperative chemoradiotherapy-a case report].
    Tanizaki K; Hama N; Tomimaru Y; Eguchi H; Akita H; Wada H; Kawamoto K; Kobayashi S; Mori M; Doki Y; Nagano H
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1872-4. PubMed ID: 24393950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
    Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
    Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
    Nakai Y; Isayama H; Sasaki T; Sasahira N; Ito Y; Kogure H; Togawa O; Matsubara S; Arizumi T; Yagioka H; Yashima Y; Kawakubo K; Mizuno S; Yamamoto K; Hirano K; Tsujino T; Ijichi H; Toda N; Tada M; Kawabe T; Omata M
    Oncology; 2009; 77(5):300-3. PubMed ID: 19923869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of locally advanced pancreas cancer effectively treated by multidisciplinary strategy].
    Hasegawa K; Katsuta E; Iwata N; Aoyagi H; Yoshida T; Takahata T; Kaneko J; Maejima S
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2152-4. PubMed ID: 22202313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
    Imaoka H; Ikeda M; Maehara K; Umemoto K; Ozaka M; Kobayashi S; Terashima T; Inoue H; Sakaguchi C; Tsuji K; Shioji K; Okamura K; Kawamoto Y; Suzuki R; Shirakawa H; Nagano H; Ueno M; Morizane C; Furuse J
    BMC Cancer; 2020 Oct; 20(1):946. PubMed ID: 33004032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
    Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is S-1 a potential game changer in adjuvant therapy of pancreatic cancer?
    Chaulagain CP; Rothschild J; Saif MW
    JOP; 2013 Jul; 14(4):329-33. PubMed ID: 23846920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer.
    Saito K; Isayama H; Sakamoto Y; Nakai Y; Ishigaki K; Tanaka M; Watadani T; Arita J; Takahara N; Mizuno S; Kogure H; Ijichi H; Tateishi K; Tada M; Hasegawa K; Fukayama M; Kokudo N; Koike K
    Med Oncol; 2018 May; 35(7):100. PubMed ID: 29846849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adjuvant gemcitabine plus S-1 chemotherapy for pancreatic cancer after surgical resection - outcomes and future perspectives].
    Murakami Y; Uemura K; Sudo T
    Nihon Shokakibyo Gakkai Zasshi; 2011 Oct; 108(10):1661-9. PubMed ID: 21971141
    [No Abstract]   [Full Text] [Related]  

  • 20. [A case report-neoadjuvant chemoradiotherapy with combination of S-1 and gemcitabine in a patient with locally advanced pancreatic cancer].
    Watanabe F; Honda G; Kurata M; Tsuruta K; Tokashiki T; Funada N
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2430-2. PubMed ID: 20037446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.